Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series by Rusz, Orsolya et al.
© 2018 Rusz et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
OncoTargets and Therapy 2018:11 5459–5463
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
5459
C a s e  s e r i e s
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S170736
Clinical benefit of fulvestrant monotherapy in 
the multimodal treatment of hormone receptor 
and Her2 positive advanced breast cancer: 
a case series
Orsolya rusz
renáta Kószó
Ágnes Dobi
Melinda Csenki
erzsébet Valicsek
alíz Nikolényi
Gabriella Uhercsák
adrienne Cserháti
Zsuzsanna Kahán
Department of Oncotherapy, 
University of Szeged, Szeged, Hungary
Abstract: Fulvestrant is a pure estrogen receptor (ER) antagonist approved for the treatment 
of metastatic ER positive breast cancer in postmenopausal women with disease progression 
following antiestrogen therapy. The clinical results of fulvestrant demonstrated encouraging 
activity in tumors in spite of HER2 positivity, but data about its use after progression on anti-
HER2 agents are limited. Partial responses and durations of response of 12, 25, and 38 months 
in three cases with multiple metastases of ER positive and HER2 positive breast cancer were 
observed; all patients had been treated with 1–4 regimens of an anti-HER2 agent in combina-
tion with chemotherapy or an aromatase inhibitor before the initiation of fulvestrant. Fulves-
trant is a valuable option with limited toxicity and durable response in metastatic HER2 and 
ER positive breast cancer after progression on anti-HER2 agents as well. Therapeutic benefit 
even in extensive skin metastases and (irradiated) brain metastases may be expected. Further 
investigations are warranted to establish where it fits into the multimodal management of ER 
and HER positive breast cancer.
Keywords: endocrine resistance, trastuzumab resistance, brain metastasis, skin metastasis
Introduction
Approximately 20% of advanced breast cancers overexpress HER2 and approxi-
mately half of them also express hormone receptors (HRs). Within the HER2 posi-
tive disease entity, the HR positive status defines an individual subset with various 
clinical behaviors, which hinders the adjustment of optimal therapeutic strategy.1,2
Although the presence of HER2 and estrogen receptor (ER) predicts benefit from 
both HER2-targeted and endocrine therapy (ET), the simultaneous activity of the 
two pathways and their bidirectional cross-talk may result in de novo or acquired 
resistance to these agents.3,4 For the delay or prevention of the development of drug 
resistance, dual inhibition appears promising.2,5 Clinical trials that investigated first-
line mono-aromatase inhibitor (mono-AI) treatment vs the combination with lapatinib 
or trastuzumab proved the superior effect of the combination, nonetheless, with no 
benefit in overall survival.6–9 Since, no studies have directly compared ET plus HER2-
targeted therapy vs chemotherapy plus HER2-targeted therapy; chemotherapy plus 
trastuzumab is still the preferred choice in HER2 and HR positive cases.10 With the 
aim of long-term control of advanced HER2 and HR positive breast cancer, optimum 
scheduling of ET should be specified.11
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Clinical studies have demonstrated that fulvestrant shows 
encouraging efficacy in HER2 positive breast cancer.12,13 In a 
retrospective study, fulvestrant retained activity in HER2 
positive breast cancer patients pretreated with trastuzumab.14 
Fulvestrant is a pure ER antagonist, binding to ER causes 
its complete blockade: receptor dimerization is impaired, 
nuclear localization is disrupted, and the bound receptor is 
rapidly degraded.2,12,13 Due to these unique features, fulves-
trant blocks the nuclear ER as well as cytoplasmic and 
membrane-bound ER which are considered to be responsible 
for ER and HER2 cross-talk.
The current case series reports three patients diagnosed 
with ER, progesterone receptor (PgR), and HER2 positive 
breast cancer with metastases at $2 sites who were treated 
with fulvestrant for $12 months after failure of anti-HER2 
regimens and ET.
Informed consent
Written informed consent was obtained from the patients for 
publication of these case reports and accompanying images. 
Consent was obtained using the standardized informed 
consent forms of our institution.
Case 1
In October 2009, inflammatory breast cancer with small cuta-
neous nodules and lymphadenopathy in the axillary and supr-
aclavicular regions was diagnosed in a 63-year-old woman. 
Histopathological examination proved ER/PgR (Allred scores 
7/7) and HER2 (IHC 3+, FISH+) positive adenocarcinoma. 
Thoracic CT revealed further pathologically enlarged lymph 
nodes around the brachiocephalic artery and aortic arch. No 
other metastatic manifestations were detected.
The patient received three lines of trastuzumab-based 
chemotherapy, which controlled the disease for 15 months 
(Figure 1). The first-line therapy with paclitaxel-trastuzumab 
resulted in partial response, but had to be stopped due to 
grade 3 sensory neuropathy. After two cycles of maintenance 
trastuzumab monotherapy, the skin metastases rapidly pro-
gressed, thus the treatment was supplemented with docetaxel. 
After sensory neuropathy deteriorated, docetaxel was imme-
diately switched to letrozole. Then, a further three lines of 
chemotherapy, palliative irradiation to the right breast, chest 
wall and lymphatic regions, and an additional two lines of 
HER2-targeted therapy (lapatinib and trastuzumab-emtansine 
[T-DM1]) were given. These all produced limited or no 
effect, the disease progressed and involved .50% of the 
chest wall resulting in the typical appearance of “carcinoma 
en cuirasse”. Having no additional anti-HER2 therapy 
options, fulvestrant (loading and then high-dose schedule 
with 500 mg every 14/28 days) was started. All cancer mani-
festations improved, and an almost complete regression was 
maintained for 2 years. After that, the introduction of letro-
zole had no effect, while consequently cyclophosphamide/
methotrexate/5-fluorouracil chemotherapy resulted in partial 
regression which lasted for 8 months. Finally, she died in 
December 2016 (Figure 1).
Case 2
In July 2010, a 41-year-old premenopausal woman with 
shortness of breath and low back pain was diagnosed with 
metastatic breast cancer. For the past year she had noticed 
deformation of the right breast. Imaging studies indicated 
locoregionally advanced disease with distant metastases in the 
lymph nodes, liver, and bones. Core biopsy from the breast 
tumor indicated grade 2 invasive ductal carcinoma, ER/PgR 
(Allred scores 8/4) and HER2 (IHC 3+, FISH+) positive.
As first-line therapy, paclitaxel-trastuzumab followed 
by trastuzumab maintenance therapy was given, which 
resulted in major partial regression at all metastatic sites, 
lasting 19 months. Then the patient developed dizziness and 
vomiting, and in addition to skeletal progression, multiple 
brain and leptomeningeal metastases were revealed. After 
whole-brain irradiation with simultaneous integrated boost 
(15× 2.2+0.7 Gy) the central nervous system (CNS) metas-
tases completely disappeared.
Following radiotherapy, the patient received eight cycles 
of cyclophosphamide-epirubicine-5-fluorouracil (CEF), 
followed by tamoxifen as maintenance therapy. This resulted 
in stable disease for 16 months altogether. Then, CNS pro-
gression was detected, and the patient (with postmenopausal 
hormone levels) was given fulvestrant (loading and then 
high-dose schedule, 500 mg every 14/28 days). During the 
treatment, the lesions in the brain decreased significantly 
(Figure 2), and all the other manifestations were stable. 
After 1 year of fulvestrant treatment, the disease progressed 
in the brain, which was re-irradiated after which T-DM1 
treatment was started. As a result, complete regression of 
the brain metastases associated with partial regression of 
the other manifestations was observed. The administration 
of T-DM1 for almost 1 year was subsequently followed by 
letrozole, which showed no activity. Therapy was continued 
with capecitabine plus lapatinib, but brain metastases still 
progressed. Almost 7 years after the first diagnosis, the 
patient died in January 2017 (Figure 1).
Case 3
In January 2012, a 50-year-old postmenopausal woman was 
referred to our department, for the past 2 years she had noticed 
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Figure 1 Treatment lines, durations, and outcomes of Cases 1–3.
Abbreviations: AC-T, doxorubicin-cyclophosphamide and sequential paclitaxel; CEF, cyclophosphamide-epirubicine-5-fluorouracil; CMF, cyclophosphamide-methotrexate-
5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease; T-DM1, trastuzumab-emtansine.
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Figure 2 Brain metastases before and 3 months after the introduction of fulvestrant therapy (Case 2).
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a palpable node in her right breast. Extensive stage T3N3 
breast cancer with multiple bone metastases was diagnosed. 
Histopathological examination revealed grade 3 invasive 
ductal cancer, ER/PgR (Allred scores 8/8) and HER2 IHC 3+ 
positive. As first-line treatment, letrozole plus trastuzumab 
was initiated. During treatment, the tumor markers (CA15-3 
and CEA) increased and 5 months later skeletal progression 
was detected. Then, following four courses of doxorubicin 
plus cyclophosphamide, paclitaxel (once every 3 weeks) 
was initiated. Tumor markers decreased to normal levels and 
partial response was detected at all metastatic sites, however, 
due to grade 3 peripheral neuropathy, paclitaxel treatment 
was terminated after 18 cycles. Then, fulvestrant (loading 
and then high-dose schedule, 500 mg every 14/28 days) was 
introduced as maintenance therapy. After 19 months of ful-
vestrant therapy, the patient presented with CNS symptoms; 
brain CT verified multiple metastatic lesions in the cerebel-
lum and parieto-occipital region. Whole brain irradiation 
with simultaneous integrated boost (14× 2.2 Gy+14× 0.8 Gy) 
was applied. Since all the extracranial tumor manifestations 
were controlled with fulvestrant, the patient remained on the 
systemic therapy; following another 14 months of fulvestrant 
therapy, no progression was detected until June 2017. At that 
time, although the brain metastases remained stable, new 
metastases in the liver and spleen, as well as progression 
of the bone metastases were diagnosed. The patient’s gen-
eral condition deteriorated continuously and she died in 
September 2017 (Figure 1).
Discussion
We reported the durable effect of fulvestrant monotherapy in 
three metastatic ER and HER2 positive breast cancer patients. 
The common features among the cases were pretreatment 
with and acquired resistance to trastuzumab; fulvestrant 
controlled disease manifestations (extensive skin involve-
ment and CNS metastases) which, according to guidelines, 
are a priori considered hormone-resistant and are primarily 
treated with chemotherapy.
Our experience is consistent with the knowledge that 
in luminal B-type breast cancers (including HER2 and 
HR positive tumors), a vulnerable balance exists between 
ER-directed and growth factor-directed driver mechanisms. 
HER2 blockade induces dependence on HR signaling which 
serves as an escape function, a probably frequent resistance 
mechanism to anti-HER2 agents in HR positive cancers.3,4 
Indeed, HER2 blockade may induce the expression of ER, 
even in originally ER negative breast cancers, as demon-
strated in the study of Giuliano et al.4 The sequential use 
of HER2 blockade and ER inhibition targets the actual 
escape mechanism evolved due to the cross-talk between 
the two driver pathways. Limited clinical data exist on the 
significance of alternating driver mechanisms in this patient 
population. Robertson et al reported the largest study about 
the activity of fulvestrant in HER2 positive breast cancer. 
In 102 heavily pretreated patients, the median duration of 
treatment was 14.5 months. The clinical benefit rate in the 
overall population was 42%, which varied according to 
whether pretreatment with trastuzumab was (46.5%) or was 
not (39%) present. Among those who responded to prior 
trastuzumab, the clinical benefit rate was 50%.14 Notably, 
while in this pooled analysis low-dose fulvestrant therapy 
of 250 mg/month was reported, our patients received the 
loading and high-dose schedule.
T-DM1 is an antibody drug conjugate that is active in 
advanced HER2 positive breast cancer after trastuzumab ther-
apy. Out of our two cases who received T-DM1, the patient 
who responded to the T-DM1 received fulvestrant prior to 
it; while the other patient, who had been treated with a series 
of chemotherapies with or without trastuzumab, but not with 
mono ET, showed resistance to T-DM1. In fact, the presence 
of HER2 in cancer cells is essential for T-DM1 efficacy and 
cases with higher HER2 mRNA levels respond more often to 
T-DM1 than those with lower HER2 expression.15 Estrogen 
deprivation with AI or fulvestrant results in the upregulation 
of HER2 in HER2 and HR positive tumors.2–4,16–18 Based on 
the preclinical and clinical findings that tumors can alter-
nate between the dominance of ER-driven or HER2-driven 
pathways,2,4,17,18 the question arises whether the use of ET 
before T-DM1 or use of ET between two lines of anti-HER2 
treatments may increase the benefits of therapy regimens. 
Moreover, this therapy sequence favors a lower incidence 
of anti-HER2 therapy-related cardiac side effects.
We found it very intriguing that fulvestrant was active 
in disease entities such as extensive skin involvement or 
CNS metastasis traditionally not treated with ET. Actually, 
fulvestrant does not cross the intact blood–brain barrier and 
knowledge about its efficacy in brain metastasis is limited.19
Recently, dual HER2 blockade with trastuzumab and 
lapatinib combined with AI in the first-line setting was 
shown to improve efficacy in the ALTERNATIVE study, 
by means of prolonged progression-free survival, higher 
response rate, and a trend of superior overall survival.20 The 
strategy of combining multiple targeted agents is aimed at 
the prevention or blockade of different resistance mecha-
nisms. The combination of new targeted therapies, such as 
the CDK4/6 inhibitors or the PI3K/mTOR inhibitors with 
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endocrine and/or anti-HER2 therapies may not only improve 
outcomes, but could serve as a preferable alternative to 
chemotherapy.21,22
Conclusion
ET is an essential component in the multimodal manage-
ment of advanced HER2 and HR positive breast cancer. 
The exact place where endocrine agents fit into multimodal 
management should be explored based on further clinical 
trials. According to our limited experience, fulvestrant is an 
especially attractive treatment option in metastatic HER2 
positive breast cancer after progression on previous HER2-
targeted treatments.
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